CTKB vs. TXG, TRNS, EYPT, ALNT, LAB, AEHR, QSI, QTRX, SENS, and MASS
Should you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Cytek Biosciences vs. Its Competitors
Cytek Biosciences (NASDAQ:CTKB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.
69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 10.3% of Cytek Biosciences shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cytek Biosciences presently has a consensus price target of $5.60, suggesting a potential upside of 72.84%. 10x Genomics has a consensus price target of $14.13, suggesting a potential upside of 14.19%. Given Cytek Biosciences' higher possible upside, equities research analysts clearly believe Cytek Biosciences is more favorable than 10x Genomics.
Cytek Biosciences has higher earnings, but lower revenue than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
In the previous week, 10x Genomics had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for 10x Genomics and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.76 beat 10x Genomics' score of 0.62 indicating that Cytek Biosciences is being referred to more favorably in the media.
Cytek Biosciences has a net margin of -5.71% compared to 10x Genomics' net margin of -25.14%. Cytek Biosciences' return on equity of -2.90% beat 10x Genomics' return on equity.
Cytek Biosciences has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.
Summary
Cytek Biosciences and 10x Genomics tied by winning 8 of the 16 factors compared between the two stocks.
Get Cytek Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytek Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CTKB) was last updated on 7/16/2025 by MarketBeat.com Staff
Free CTKB Stock Alerts